Artwork

Contenuto fornito da Lynn Marie Morski, MD, and JD. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da Lynn Marie Morski, MD, and JD o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.
Player FM - App Podcast
Vai offline con l'app Player FM !

Psychedelics for Postpartum Mood Disorders with Melissa Whippo, LCSW

36:01
 
Condividi
 

Manage episode 400938757 series 3468391
Contenuto fornito da Lynn Marie Morski, MD, and JD. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da Lynn Marie Morski, MD, and JD o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.

In this episode of the Psychedelic Medicine Podcast we discuss the topic of psychedelics and postpartum mood disorders. Melissa Whippo is a licensed psychotherapist who specializes in the intersection of women's health and psychedelics. She founded a non-profit, Deva Collective, which has fiscal sponsorship with MAPS, and is currently conducting research about perimenopause and microdosing San Pedro.

In this conversation, Melissa shares the details of existing research into psychedelic treatments for postpartum populations. She discusses the findings from her study on “The Pharmacokinetics of Ketamine in the Breast Milk of Lactating Women,” reporting that ketamine was not detected at all in breast milk twelve hours after dosing. She also shares information on parents’ intentional use of microdosing and what motivates them to take up this practice. In closing, Melissa discusses her upcoming research on microdosing San Pedro among perimenopausal populations and why she decided to focus on San Pedro for this study.

In this episode you'll hear:

  • The early research into ketamine for postpartum depression and whether ketamine remains in breast milk
  • The prevalence of mood concerns in the postpartum population
  • Issues of access with ketamine treatments for new mothers
  • Improvements in postpartum mood patients following ketamine treatments that Melissa has seen in her practice
  • Hormone changes after giving birth and how this might relate to mood concerns
  • Ketamine for postpartum pain

Quotes:

“The reason why ketamine and other psychedelics appeal to me more [than other treatments for postpartum depression], is it’s not a medicine you have to take every day and it’s not a medicine that’s going to cause a significant separation [with the newborn] like a hospital admission would.” [5:55]

“More SSRI—which is still considered safe by the medical profession—passes through the breastmilk than ketamine. Probably nanograms. And ketamine has such a short half-life in the system, particularly with the intramuscular route of administration, that twelve hours after dosing, the breast milk was completely clear.” [14:22]

“That’s what ketamine does so well—it gives people a different view of some of the things they’re really struggling with that they can’t quite break through. Some of these more recursive ruminations that seem to befall mothers quite a bit—and they’re usually pretty negative. But the medicine space gives them a different view.” [18:52]

Links:

Melissa’s study: The Pharmacokinetics of Ketamine in the Breast Milk of Lactating Women: Quantification of Ketamine and Metabolites

Melissa’s article in the Washington Post: Some moms are microdosing mushrooms for anxiety and depression

Melissa’s website

Deva Collective website

Melissa on Instagram

Plant Parenthood website

Previous episode: Psychedelics and Women’s Health with Allison Feduccia, PhD

Psychedelic Medicine Association

Porangui

  continue reading

167 episodi

Artwork
iconCondividi
 
Manage episode 400938757 series 3468391
Contenuto fornito da Lynn Marie Morski, MD, and JD. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da Lynn Marie Morski, MD, and JD o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.

In this episode of the Psychedelic Medicine Podcast we discuss the topic of psychedelics and postpartum mood disorders. Melissa Whippo is a licensed psychotherapist who specializes in the intersection of women's health and psychedelics. She founded a non-profit, Deva Collective, which has fiscal sponsorship with MAPS, and is currently conducting research about perimenopause and microdosing San Pedro.

In this conversation, Melissa shares the details of existing research into psychedelic treatments for postpartum populations. She discusses the findings from her study on “The Pharmacokinetics of Ketamine in the Breast Milk of Lactating Women,” reporting that ketamine was not detected at all in breast milk twelve hours after dosing. She also shares information on parents’ intentional use of microdosing and what motivates them to take up this practice. In closing, Melissa discusses her upcoming research on microdosing San Pedro among perimenopausal populations and why she decided to focus on San Pedro for this study.

In this episode you'll hear:

  • The early research into ketamine for postpartum depression and whether ketamine remains in breast milk
  • The prevalence of mood concerns in the postpartum population
  • Issues of access with ketamine treatments for new mothers
  • Improvements in postpartum mood patients following ketamine treatments that Melissa has seen in her practice
  • Hormone changes after giving birth and how this might relate to mood concerns
  • Ketamine for postpartum pain

Quotes:

“The reason why ketamine and other psychedelics appeal to me more [than other treatments for postpartum depression], is it’s not a medicine you have to take every day and it’s not a medicine that’s going to cause a significant separation [with the newborn] like a hospital admission would.” [5:55]

“More SSRI—which is still considered safe by the medical profession—passes through the breastmilk than ketamine. Probably nanograms. And ketamine has such a short half-life in the system, particularly with the intramuscular route of administration, that twelve hours after dosing, the breast milk was completely clear.” [14:22]

“That’s what ketamine does so well—it gives people a different view of some of the things they’re really struggling with that they can’t quite break through. Some of these more recursive ruminations that seem to befall mothers quite a bit—and they’re usually pretty negative. But the medicine space gives them a different view.” [18:52]

Links:

Melissa’s study: The Pharmacokinetics of Ketamine in the Breast Milk of Lactating Women: Quantification of Ketamine and Metabolites

Melissa’s article in the Washington Post: Some moms are microdosing mushrooms for anxiety and depression

Melissa’s website

Deva Collective website

Melissa on Instagram

Plant Parenthood website

Previous episode: Psychedelics and Women’s Health with Allison Feduccia, PhD

Psychedelic Medicine Association

Porangui

  continue reading

167 episodi

Tutti gli episodi

×
 
Loading …

Benvenuto su Player FM!

Player FM ricerca sul web podcast di alta qualità che tu possa goderti adesso. È la migliore app di podcast e funziona su Android, iPhone e web. Registrati per sincronizzare le iscrizioni su tutti i tuoi dispositivi.

 

Guida rapida